–
A new blood test which can detect breast cancer has been developed by Israeli scientific researchers.
–
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
–
Mosahv Ora, near Jerusalem, is home to the research and development facility of Miami based Eventus Diagnostics. This is where the company has developed a blood test to screen patients for breast cancer. Eventus says that this is an accurate, cost effective immune system based test which can detect the presence of cancer cells in a person’s breast tissue.
Called the Octava test, EventusDX has developed a way to measure breast cancer specific anti-bodies in order to detect the presence or absence of breast cancer. The Octava test is intended for use together with annual screenings and mammograms. It has been validated by clinical studies conducted at cancer research centers in the US, Israel and Italy where the blood samples of 800 women were tested.
A patient must provide a small sample of plasma to quickly determine the presence of the antibodies when undergoing the two chip-based tests, called Octava Pink and Octava Blue.
In April Eventus announced that it had secured $2.72 million in funding to finance the commercialization of Octavia. The money went towards paying for the trials that are required by America’s Food and Drug Administration. The company said it was also trying to develop similar methods to diagnose other forms of cancer.
Eventus said in a statement, “The company’s core technology has the unique ability to accurately determine whether cancer is present by identifying and measuring certain combinations of these cancer-specific autoantibodies. The ability to assess these combinations to distinguish between healthy individuals and those with cancer is the foundation of the Eventus technology. Researchers have long realized that profiling the antibody repertoire of the immune system could potentially detect cancer in its early stages, even before the cancer is clinically evident. These findings led EventusDx scientists to develop methods to accurately identify these breast cancer-specific autoantibodies that could be used for early detection of the disease.”
The president and chairman of Eventus, Dr. Mavin Rosenberg, oversees the company’s operations in the United States. Previously, he maintained successful periodontology and implantology practices in West Palm Beach and Boca Raton, Florida. Dr. Rosenberg graduated from New York University College of Dentistry and received his postdoctoral training in Periodontology at the University of Pennsylvania Graduate School of Medicine and Boston University School of Medicine, and he served as a National Institutes of Health Research Fellow in the field of immunology.
Co founder and president of Eventus Israel, Alon Hyka holds undergraduate and masters degrees from Hebrew University.
